TY - JOUR
T1 - External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium
T2 - A meta-analysis and systemic review
AU - Rim, Chai Hong
AU - Kim, Chul Yong
AU - Yang, Dae-Sik
AU - Yoon, Won Sup
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Purpose: Hepatocellular carcinoma (HCC) involving inferior vena cava (IVC) and/or right atrium (RA) is a very rare but serious disease. The objective of this meta-analysis was to assess efficacy and safety of external beam radiotherapy (EBRT) for HCC involving IVC and/or RA. Materials and methods: Systematic search of Pubmed, MEDLINE, EMBASE, and Cochrane library published was performed. Primary endpoints were 1-year overall survival (OS) rate and 2-year OS rates. Secondary endpoints were response rate, local control (LC) rate, and grade ≥3 toxicities. According to heterogeneity evaluated with Cochran Q test and I2 statistics, meta-analysis was performed using either random or fixed model. Results: A total of 8 studies and 9 cohorts were included, encompassing 164 patients. Pooled 1- and 2-year OS rates were 53.6% (95% CI: 45.7–61.3%) and 36.9% (95% CI: 27.2–42.4%), respectively. Pooled response rate and LC rate were 59.2% (95% CI: 39.0–76.7%) and 83.8% (95% CI: 78.8–97.1%), respectively. Only one study reported 2 grade ≥3 toxicities, an esophageal rupture and a pulmonary embolism cases. The overall rate of possible grade ≥3 complications was 1.2% (2 of 164). Conclusions: EBRT is a feasible and safe option to palliate HCC with IVC and/or RA invasion.
AB - Purpose: Hepatocellular carcinoma (HCC) involving inferior vena cava (IVC) and/or right atrium (RA) is a very rare but serious disease. The objective of this meta-analysis was to assess efficacy and safety of external beam radiotherapy (EBRT) for HCC involving IVC and/or RA. Materials and methods: Systematic search of Pubmed, MEDLINE, EMBASE, and Cochrane library published was performed. Primary endpoints were 1-year overall survival (OS) rate and 2-year OS rates. Secondary endpoints were response rate, local control (LC) rate, and grade ≥3 toxicities. According to heterogeneity evaluated with Cochran Q test and I2 statistics, meta-analysis was performed using either random or fixed model. Results: A total of 8 studies and 9 cohorts were included, encompassing 164 patients. Pooled 1- and 2-year OS rates were 53.6% (95% CI: 45.7–61.3%) and 36.9% (95% CI: 27.2–42.4%), respectively. Pooled response rate and LC rate were 59.2% (95% CI: 39.0–76.7%) and 83.8% (95% CI: 78.8–97.1%), respectively. Only one study reported 2 grade ≥3 toxicities, an esophageal rupture and a pulmonary embolism cases. The overall rate of possible grade ≥3 complications was 1.2% (2 of 164). Conclusions: EBRT is a feasible and safe option to palliate HCC with IVC and/or RA invasion.
KW - Hepatocellular carcinoma
KW - Inferior vena cava
KW - Meta-analysis
KW - Radiotherapy
KW - Right atrium
UR - http://www.scopus.com/inward/record.url?scp=85044527562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044527562&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2018.02.030
DO - 10.1016/j.radonc.2018.02.030
M3 - Article
C2 - 29606524
AN - SCOPUS:85044527562
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
SN - 0167-8140
ER -